Development and Surveillance of Hepatocellular Carcinoma in Patients with Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2019 Jan 22

PMID 30661334

Citations 19

Authors

Seong Kyun Na

Byung-Cheol Song

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5-4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC.

Citing Articles

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?.

Smirne C, Crobu M, Landi I, Vercellino N, Apostolo D, Pinato D Viruses. 2025; 16(12.

PMID: 39772206 PMC: 11680226. DOI: 10.3390/v16121899.

M2BPgs-HCC: An Automated Multilectin Bead Array Indicating Aberrant Glycosylation Signatures Toward Hepatitis C Virus-Associated Hepatocellular Carcinoma Prognosis.

Shimazaki H, Uojima H, Yamasaki K, Obayashi T, Fuseya S, Sato T Molecules. 2024; 29(23).

PMID: 39683799 PMC: 11643838. DOI: 10.3390/molecules29235640.

Reply to correspondence on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".

Gedallovich S, Kwo P Clin Mol Hepatol. 2024; 30(4):1050-1052.

PMID: 38993076 PMC: 11540377. DOI: 10.3350/cmh.2024.0546.

Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data.

Zou Y, Yue M, Jia L, Wang Y, Chen H, Zhang A BMC Cancer. 2023; 23(1):1147.

PMID: 38007418 PMC: 10676612. DOI: 10.1186/s12885-023-11628-1.

A Survey of Liver Cancer Specialists' Views on the National Liver Cancer Screening Program in Korea.

Sohn W, Lee Y, Lee J, An J, Jang E, Lee D J Liver Cancer. 2023; 20(1):53-59.

PMID: 37383049 PMC: 10035697. DOI: 10.17998/jlc.20.1.53.

References

Janjua N, Chong M, Kuo M, Woods R, Wong J, Yoshida E . Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2016; 66(3):504-513. DOI: 10.1016/j.jhep.2016.10.028. View

El-Serag H, Kanwal F, Richardson P, Kramer J . Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016; 64(1):130-7. PMC: 4917456. DOI: 10.1002/hep.28535. View

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H . Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005; 40(2):148-56. DOI: 10.1007/s00535-004-1519-2. View

Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H . Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2007; 23(3):437-44. DOI: 10.1111/j.1440-1746.2007.05054.x. View

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M . Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67(6):1204-1212. DOI: 10.1016/j.jhep.2017.07.025. View

Sherman M . Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014; 28(5):783-93. DOI: 10.1016/j.bpg.2014.08.008. View

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

Lin O, Keeffe E, Sanders G, Owens D . Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004; 19(11):1159-72. DOI: 10.1111/j.1365-2036.2004.01963.x. View

Li D, Ren Y, Fierer D, Rutledge S, Shaikh O, Lo Re 3rd V . The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2017; 67(6):2244-2253. DOI: 10.1002/hep.29707. View

10.

Yu M, Lin S, Lee C, Dai C, Chang W, Chen S . A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology. 2006; 44(5):1086-97. DOI: 10.1002/hep.21363. View

11.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

12.

Lin Z, Xin Y, Dong Q, Wang Q, Jiang X, Zhan S . Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3):726-36. DOI: 10.1002/hep.24105. View

13.

Lee H, Chon Y, Kim S, Kim B, Park J, Kim D . Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. Gut Liver. 2015; 10(3):429-36. PMC: 4849697. DOI: 10.5009/gnl15021. View

14.

Ioannou G, Green P, Berry K . HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017; . PMC: 5837901. DOI: 10.1016/j.jhep.2017.08.030. View

15.

Huang C, Yeh M, Tsai P, Hsieh M, Yang H, Hsieh M . Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014; 61(1):67-74. DOI: 10.1016/j.jhep.2014.02.022. View

16.

Lavanchy D . Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2010; 17(2):107-15. DOI: 10.1111/j.1469-0691.2010.03432.x. View

17.

Kanwal F, Kramer J, Asch S, Chayanupatkul M, Cao Y, El-Serag H . Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153(4):996-1005.e1. DOI: 10.1053/j.gastro.2017.06.012. View

18.

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

19.

Morgan R, Baack B, Smith B, Yartel A, Pitasi M, Falck-Ytter Y . Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5 Pt 1):329-37. DOI: 10.7326/0003-4819-158-5-201303050-00005. View

20.

Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire B . Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. Gastroenterology. 2017; 152(4):911-912. DOI: 10.1053/j.gastro.2016.12.021. View